Most obesity drugs do not improve quality of life or heart health, analysis indicates
· Medical Xpressedited by Sadie Harley, reviewed by Andrew Zinin
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Despite substantial weight loss, most obesity drugs such as Wegovy and Mounjaro do not meaningfully improve quality of life, and few show cardiovascular benefits at one year, according to an analysis of the latest evidence published by The BMJ.
More weight loss is also generally accompanied by greater harms, including stomach and bowel symptoms, fatigue and loss of lean (muscle) mass, and improvements are not sustained after stopping treatment.
Several drugs for adults with overweight or obesity produce substantial weight loss, but most have not been compared directly in head-to-head trials, leaving uncertainty about the broader balance of benefits and harms.
To address this, researchers searched scientific databases for randomized controlled trials comparing one or more drugs with lifestyle changes, placebo or another drug.
They found 262 eligible trials involving 99,791 participants (average age 49; 63% female; average BMI 35) that evaluated 19 currently available and emerging obesity drugs with follow-up ranging from 12 to 172 weeks.
Benefits included changes in body weight, fat mass and quality of life, while potential harms included changes in lean mass, gastrointestinal adverse events, gallbladder-related disorders and fatigue.
The trials were of varying quality, but the researchers were able to assess the certainty of evidence using the recognized GRADE system.
Big losses, bigger trade-offs
Compared with lifestyle changes alone, the largest weight loss after one year was with tirzepatide (14.9%) and CagriSema (14.8%), followed by oral semaglutide (10.9%), orforglipron (9.9%), subcutaneous semaglutide (9.8%) and phentermine-topiramate (8.1%).
Emerging drugs—including retatrutide, ecnoglutide and mazdutide—showed large effects on weight loss but are supported by low- or very low-certainty evidence.
Greater weight loss was consistently accompanied by higher rates of side effects and treatment discontinuation, which the authors say indicates a clear benefit-harm trade-off.
Cardiac gains remain limited
Tirzepatide reduced fat mass the most (by 25.7%) but also lean mass the most (8.3%). Subcutaneous semaglutide was the only drug associated with a reduced risk of death from any cause (19%), heart attack (28%) and heart failure (57%). Tirzepatide also reduced heart failure risk by 51%.
No drug convincingly reduced kidney failure or showed clinically important improvements in quality of life.
Gaps in the longer view
The authors acknowledge that most trials had relatively short follow-up, limiting conclusions about long-term safety, quality of life and effects on heart and kidney health. In addition, evidence for several newer drugs was sparse and of low certainty, and trial populations may not fully represent real-world patients.
However, they say this review provides a comprehensive and up-to-date comparison of currently available and emerging obesity drugs across a broad set of outcomes important to patients, clinicians and policymakers.
They conclude: "Treatment decisions for obesity should be individualized, balancing expected benefits, harms, treatment burden, costs, availability, and patient preferences."
This study represents an important step in providing comparative information to inform patient-clinician discussions about obesity drugs in this rapidly evolving landscape of treatment options, researchers say in a linked editorial.
And they suggest future studies that incorporate individual characteristics, as well as long-term outcomes such as mortality, should provide additional data to inform individualized decision-making.
Publication details
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis, The BMJ (2026). DOI: 10.1136/bmj-2026-372161
Journal information: British Medical Journal (BMJ)
Key medical concepts
Anti-Obesity AgentsQuality of LifeHeart FailureRandomized Controlled Trials as Topic
Clinical categories
EndocrinologyWeight managementClinical pharmacology Provided by British Medical Journal Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Most obesity drugs do not improve quality of life or heart health, analysis indicates (2026, July 8) retrieved 9 July 2026 from https://medicalxpress.com/news/2026-07-obesity-drugs-quality-life-heart.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.